<?xml version='1.0' encoding='utf-8'?>
<document id="21436403"><sentence text="Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase."><entity charOffset="51-60" id="DDI-PubMed.21436403.s1.e0" text="veliparib" /><entity charOffset="104-120" id="DDI-PubMed.21436403.s1.e1" text="poly(ADP-ribose)" /><pair ddi="false" e1="DDI-PubMed.21436403.s1.e0" e2="DDI-PubMed.21436403.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21436403.s1.e0" e2="DDI-PubMed.21436403.s1.e1" /></sentence><sentence text="The disposition of veliparib [(R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide, ABT-888], a novel and potent inhibitor of poly(ADP-ribose) polymerase for the treatment of cancers, was investigated in rats and dogs after intravenous and oral administration of [(3)H]veliparib and compared with that of humans"><entity charOffset="19-96" id="DDI-PubMed.21436403.s2.e0" text="veliparib [(R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide" /><entity charOffset="98-106" id="DDI-PubMed.21436403.s2.e1" text="ABT-888]" /><entity charOffset="140-156" id="DDI-PubMed.21436403.s2.e2" text="poly(ADP-ribose)" /><entity charOffset="277-292" id="DDI-PubMed.21436403.s2.e3" text="[(3)H]veliparib" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e0" e2="DDI-PubMed.21436403.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e0" e2="DDI-PubMed.21436403.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e0" e2="DDI-PubMed.21436403.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e0" e2="DDI-PubMed.21436403.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e1" e2="DDI-PubMed.21436403.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e1" e2="DDI-PubMed.21436403.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e1" e2="DDI-PubMed.21436403.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e2" e2="DDI-PubMed.21436403.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21436403.s2.e2" e2="DDI-PubMed.21436403.s2.e3" /></sentence><sentence text=" Veliparib absorption was high"><entity charOffset="1-10" id="DDI-PubMed.21436403.s3.e0" text="Veliparib" /></sentence><sentence text=" Dosed radioactivity was widely distributed in rat tissues" /><sentence text=" The majority of drug-related material was excreted in urine as unchanged drug (approximately 54, 41, and 70% of the dose in rats, dogs, and humans, respectively)" /><sentence text=" A lactam M8 and an amino acid M3 were two major excretory metabolites in animals"><entity charOffset="3-12" id="DDI-PubMed.21436403.s6.e0" text="lactam M8" /><entity charOffset="20-30" id="DDI-PubMed.21436403.s6.e1" text="amino acid" /><pair ddi="false" e1="DDI-PubMed.21436403.s6.e0" e2="DDI-PubMed.21436403.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21436403.s6.e0" e2="DDI-PubMed.21436403.s6.e1" /></sentence><sentence text=" In the circulation of animals and humans, veliparib was the major drug-related component, and M8 was one of the major metabolites"><entity charOffset="43-52" id="DDI-PubMed.21436403.s7.e0" text="veliparib" /></sentence><sentence text=" Monooxygenated metabolite M2 was significant in the rat and dog, and M3 was also significant in the dog" /><sentence text=" Veliparib biotransformation occurred on the pyrrolidine moiety via formation of a lactam, an amino acid, and an N-carbamoyl glucuronide, in addition to oxidation on benzoimidazole carboxamide and sequential glucuronidation"><entity charOffset="1-10" id="DDI-PubMed.21436403.s9.e0" text="Veliparib" /><entity charOffset="45-56" id="DDI-PubMed.21436403.s9.e1" text="pyrrolidine" /><entity charOffset="83-89" id="DDI-PubMed.21436403.s9.e2" text="lactam" /><entity charOffset="94-104" id="DDI-PubMed.21436403.s9.e3" text="amino acid" /><entity charOffset="113-136" id="DDI-PubMed.21436403.s9.e4" text="N-carbamoyl glucuronide" /><entity charOffset="166-192" id="DDI-PubMed.21436403.s9.e5" text="benzoimidazole carboxamide" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e0" e2="DDI-PubMed.21436403.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e0" e2="DDI-PubMed.21436403.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e0" e2="DDI-PubMed.21436403.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e0" e2="DDI-PubMed.21436403.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e0" e2="DDI-PubMed.21436403.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e0" e2="DDI-PubMed.21436403.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e1" e2="DDI-PubMed.21436403.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e1" e2="DDI-PubMed.21436403.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e1" e2="DDI-PubMed.21436403.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e1" e2="DDI-PubMed.21436403.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e1" e2="DDI-PubMed.21436403.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e2" e2="DDI-PubMed.21436403.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e2" e2="DDI-PubMed.21436403.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e2" e2="DDI-PubMed.21436403.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e2" e2="DDI-PubMed.21436403.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e3" e2="DDI-PubMed.21436403.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e3" e2="DDI-PubMed.21436403.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e3" e2="DDI-PubMed.21436403.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e4" e2="DDI-PubMed.21436403.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21436403.s9.e4" e2="DDI-PubMed.21436403.s9.e5" /></sentence><sentence text=" In vitro experiments using recombinant human cytochrome P450 (P450) enzymes identified CYP2D6 as the major enzyme metabolizing veliparib with minor contributions from CYP1A2, 2C19, and 3A4" /><sentence text=" Veliparib did not inhibit or induce the activities of major human P450s"><entity charOffset="1-10" id="DDI-PubMed.21436403.s11.e0" text="Veliparib" /></sentence><sentence text=" Veliparib was a weak P-glycoprotein (P-gp) substrate, showing no P-gp inhibition"><entity charOffset="1-10" id="DDI-PubMed.21436403.s12.e0" text="Veliparib" /></sentence><sentence text=" Taken together, these studies indicate a low potential for veliparib to cause clinically significant P-gp or P450-mediated drug-drug interactions (DDIs)"><entity charOffset="60-69" id="DDI-PubMed.21436403.s13.e0" text="veliparib" /></sentence><sentence text=" Overall, the favorable dispositional and DDI profiles of veliparib should be beneficial to its safety and efficacy"><entity charOffset="58-67" id="DDI-PubMed.21436403.s14.e0" text="veliparib" /></sentence><sentence text="" /></document>